Ipamorelin 10mg — Research Protocol Reference

Ipamorelin is administered via subcutaneous injection twice daily throughout the active cycle.

Both injections should align with the body's natural GH secretion windows, once before bed to amplify the nocturnal GH pulse, and once fasted in the morning or immediately post-training. Ipamorelin's half-life of approximately 2 hours means each injection produces a discrete GH pulse that peaks and clears before the next dose, making injection timing relative to sleep, fasting state, and training the most important variable in the protocol.

Do not use Ipamorelin if you have active malignancy, diabetic retinopathy, or hypersensitivity to GH secretagogues. Monitor fasting glucose during the active cycle, sustained GH elevation can reduce insulin sensitivity at higher doses or over prolonged cycles.

Ipamorelin is a selective GHRP with a half-life of approximately 2 hours, producing a clean pulsatile GH release without raising cortisol, prolactin, or ACTH at therapeutic doses, a selectivity profile confirmed in published clinical research and the primary reason it is the preferred GHRP in clinical GH optimisation protocols. The twice-daily frequency maintains two deliberate GH pulses across the day aligned with sleep and training. The 4-week rest period allows pituitary ghrelin receptor sensitivity to restore before the next cycle.

In biohacking forums, Ipamorelin is almost universally stacked with CJC-1295 No DAC at a 1:1 ratio, dosed together twice daily before bed and fasted in the morning or post-training. It is favoured over GHRP-2 and GHRP-6 specifically for its selectivity, no cortisol spike, no prolactin rise, and minimal appetite stimulation. These are community-derived patterns, not clinical.

Ipamorelin is injected subcutaneously twice daily. Timing both doses to natural GH secretion windows maximises the response from each injection.

• Dose 1, before bed (primary dose): The largest natural GH pulse occurs 60–90 minutes after sleep onset. Injecting 15–30 minutes before bed positions the Ipamorelin peak to overlap with and amplify this nocturnal pulse, the most important dose of the two for recovery and repair.
• Dose 2, fasted morning or immediately post-training: A fasted state and acute exercise are the two strongest natural GH triggers outside of sleep. Injecting on an empty stomach in the morning, or within 15 minutes of finishing a training session, captures this window for maximum anabolic and lipolytic effect.
• Avoid dosing within 2 hours of a high-carbohydrate meal: Elevated insulin directly suppresses GH secretion. Dosing in a fed state significantly reduces the GH pulse amplitude. Keep both injection windows in a fasted or low-insulin state wherever possible.
• Draw each dose fresh: Do not pre-draw doses into syringes for later use. Draw at injection time from the refrigerated vial each session.
• Rotate injection sites every session: With twice-daily dosing across a 12-week cycle, consistent rotation across the abdomen and outer thighs prevents site irritation and lipodystrophy.

• Stack with CJC-1295 No DAC for maximum GH output: Ipamorelin activates the ghrelin receptor to trigger its own GH pulse. CJC-1295 No DAC activates the GHRH receptor through a separate pathway. Together they produce a synergistic GH release significantly greater than either alone. The standard stack ratio is 1:1 at the same dose and timing, both injected simultaneously from separate syringes or combined in the same draw.
• Selectivity is the defining advantage: Ipamorelin does not raise cortisol, prolactin, or appetite at standard doses. This makes it appropriate for longer cycles and daily use in a way that GHRP-2 and GHRP-6 are not. Do not substitute with other GHRPs and expect the same side effect profile.
• Effects build over weeks: IGF-1 elevation is cumulative. Meaningful body composition and recovery changes typically become apparent at weeks 4–6. Do not adjust dose based on early cycle response.
• Monitor fasting glucose at weeks 4 and 8: Sustained GH elevation reduces insulin sensitivity in some individuals. A mid-cycle bloodwork check catches any glucose dysregulation early.
• Discard at 28–30 days post-reconstitution. With twice-daily dosing at 200mcg, a 10mg vial provides approximately 25 injection pairs, well within the 28–30 day window.

Taking too much Ipamorelin can increase side effects. Signs your dose may be too high:

• Water retention and puffiness: The most common above-range sign. GH drives fluid retention, particularly in the hands, feet, and face. Reduce to 200mcg per injection if persistent beyond the first two weeks.
• Joint pain or carpal tunnel symptoms: Fluid accumulation in joint capsules from elevated GH. Tingling or numbness in the hands is a reliable signal to reduce dose immediately.
• Headache shortly after injection: Reported at higher doses across GHRP protocols. Reduce to the previous dose step and allow one week to normalise before reassessing.
• Elevated fasting glucose: GH reduces insulin sensitivity at above-range doses. If fasting glucose rises above personal baseline, reduce dose and recheck within two weeks.
• Flushing or light-headedness post-injection: Transient and dose-dependent. Reduce to 100mcg per injection if it occurs consistently.

If any of these occur, reduce to 100mcg per injection and hold for one week before attempting to advance again.

A dose may be too low if expected effects are absent after consistent use. Common indicators:

• No improvement in sleep quality or recovery after 3–4 weeks at maintenance: Confirm the before-bed dose is being administered within 30 minutes of sleep and in a fasted or low-insulin state. Sleep improvement is the earliest and most consistent indicator of a working Ipamorelin protocol.
• No change in body composition after 6 weeks at 200mcg twice daily: Confirm injection technique, fasted timing at both windows, and that both doses are being administered consistently. If all confirmed, advancing to 300mcg per injection is within the documented range.
• No water retention at all in the first two weeks: Mild transient fluid retention is expected at therapeutic doses. Complete absence alongside no other effects may indicate underdosing or technique issues, confirm micro needle draw accuracy before adjusting.

If these indicators persist after a full 6-week maintenance phase with correct timing and technique, advancing to 300mcg (~9 units) per injection for the remainder of the cycle is appropriate.

⚠️ This is for informational purposes only. For medical advice or diagnosis, consult a professional. ⚠️